Research programme: allogeneic CAR-T cell therapies - Ucello Therapeutics
Latest Information Update: 16 Mar 2022
At a glance
- Originator Ucello Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Haematological malignancies; Solid tumours